You are here

The FDA Approves Lithium Carbonate Extended-Release Tablets, Generic Version of Lithobid

SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--April 22, 2003-- Able Laboratories, Inc. (Nasdaq:ABRX - News; BSE:AAB - News), today announced that it has received Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Lithium Carbonate Extended-Release Tablets, USP 300mg, which is therapeutically equivalent to Lithobid® Slow-Release Tablets, USP 300mg, of Solvay Pharmaceuticals, Inc. The total market for Able's newly approved drug (used in the treatment of episodes of manic depressive illness) is estimated to be approximately $27 million according to recent market data.

Although Able is the second company to receive an ANDA approval for this product, Able anticipates it will be the first company to ship the generic equivalent of Lithobid® Slow-Release Tablets.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Since March 2001, Able has received 28 ANDA approvals. Further information on Able may be found on the Company's web site,

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug